Kemper Corporation KMPR divested Reserve National Insurance Company and its subsidiaries to Medical Mutual of Ohio for $88 million in cash. The divesture will allow this Zacks Rank #3 (Hold) insurer to intensify its focus on its core capabilities. The transaction was announced on Aug 1, 2022.Based in Oklahoma City, Reserve National sells accident and health insurance products in both the individual and group markets. The unit wrote more than $170 million premiums in 2021. Headquartered in Cleveland, Medical Mutual is one of Ohio’s oldest and largest health insurance companies. The company provides health, life, disability, dental, vision and indemnity plans to its customers. Thus, the addition of Reserve National to Medical Mutual’s portfolio will help the acquirer expand its presence and strengthen its product portfolio.Kemper stays focused on building its P&C and life insurance businesses that provide sustainable, competitive advantages. In tandem with its business focus and enhanced operating model, the insurer has initiated a strategic review of Kemper Personal Insurance, which is the preferred home and auto business.Kemper has also laid out strategic initiatives to strengthen competitive advantages and accelerate growth. The insurer stated this includes programs to enhance and optimize expenses within LAE, enterprise expense and real estate. While KMPR estimates more than $150 million annualized expense savings, it also expects to incur $150 million to $200 million over the next three years to achieve the expense savings.Shares of this multi-line insurer have lost 5.1% year to date against the industry's increase of 0.1%. A compelling product portfolio, lower investment expenses, strong segmental performance and ample liquidity should help the stock bounce back.Image Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks from the multi-line insurance industry are MGIC Investment Corporation MTG, Radian Group Inc. RDN and Allianz SE ALIZY, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.MGIC Investment’s earnings surpassed estimates in each of the last four quarters, the average being 36.34%. In the past year, MGIC Investment has lost 10.5%.The Zacks Consensus Estimate for MTG’s 2022 and 2023 earnings has moved 12.1% and 0.4% north, respectively, in the past 30 days. Radian Group’s earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 45.10%.The Zacks Consensus Estimate for RDN’s 2022 earnings has moved 12.7% north in the past 30 days. In the past year, the insurer has lost 12.5%.Allianz’s earnings surpassed estimates in each of the last four quarters, the average earnings surprise being 12.96%. In the past year, the insurer has lost 8.2%.The Zacks Consensus Estimate for ALIZY’s 2022 and 2023 earnings has moved 4.4% and 3.8% north, respectively, in the past 30 days. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MGIC Investment Corporation (MTG): Free Stock Analysis Report Radian Group Inc. (RDN): Free Stock Analysis Report Kemper Corporation (KMPR): Free Stock Analysis Report Allianz SE (ALIZY): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research